• Product Name:Opicapone
  • Molecular Formula:C15H10Cl2N4O6
  • Purity:99%
  • Molecular Weight:413.174

Product Details:

CasNo: 923287-50-7

Molecular Formula: C15H10Cl2N4O6

Quality Manufacturer Supply Top Purity Opicapone 923287-50-7 Cheap Price

  • Molecular Formula:C15H10Cl2N4O6
  • Molecular Weight:413.174
  • Boiling Point:701.1±70.0 °C (760 mmHg) 
  • PKA:4.67±0.38(Predicted) 
  • PSA:150.66000 
  • Density:1.80±0.1 g/cm3 (20 °C, 760 mmHg) 
  • LogP:4.59830 

Opicapone(Cas 923287-50-7) Usage

Opicapone is a medication used in conjunction with levodopa and carbidopa (commonly found in medications like Sinemet and Rytary) to address the end-of-dose "wearing-off" symptoms associated with Parkinson's disease. It belongs to the category of catechol-O-methyltransferase (COMT) inhibitors.

Parkinson's disease is a neurodegenerative disorder characterized by both motor and non-motor symptoms. Levodopa is considered the gold standard for symptom management in Parkinson's disease. However, after around two years of treatment, approximately half of patients experience fluctuations in motor performance. This is where COMT inhibitors like Opicapone become essential.

Opicapone, marketed under the brand name Ongentys, is a potent third-generation COMT inhibitor. Its mechanism of action involves inhibiting COMT, an enzyme responsible for metabolizing levodopa. By inhibiting COMT, Opicapone enhances the bioavailability and duration of action of levodopa, leading to more consistent symptom control throughout the day.

923287-50-7 Relevant articles

Opicapone for the treatment of Parkinson’s disease: an update

András Salamon,Dénes Zádori,László Szpisjak,Péter Klivényi &László Vécsei

, Expert Opinion on Pharmacotherapy Volume 20, 2019 - Issue 18

This article summarizes our knowledge about a new third-generation COMT inhibitor, namely opicapone (OPC) (Search period: 2016–2019). The authors detail the pharmacological profile of OPC and summarize the results of completed clinical trials. In addition, they briefly summarize the achievements of the past few years.

Opicapone: A Review in Parkinson’s Disease

Adis Drug Evaluation

Drugs, Volume 76, pages 1293–1300, (2016)

No new unexpected safety concerns were identified after ≈1.4 years’ treatment with opicapone, with no serious cases of hepatotoxicity reported in clinical trials. With its convenient once-daily regimen, oral opicapone is an emerging COMT inhibitor option for use as adjunctive therapy to L-Dopa/DDCI therapy in adults with PD and end-of dose motor fluctuations who cannot be stabilized on those combinations.

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial

Prof Joaquim J Ferreira, MD Prof Andrew Lees, MD José-Francisco Rocha, BSc Prof Werner Poewe, MD Prof Olivier Rascol, MD Prof Patrício Soares-da-Silva, MD

The Lancet Choice, VOLUME 15, ISSUE 2, P154-165, FEBRUARY 2016

Treatment with opicapone 50 mg was superior to placebo (mean difference in change from baseline −60·8 min, 95% CI −97·2 to −24·4; p=0·0015) and non-inferior to entacapone (−26·2 min, −63·8 to 11·4; p=0·0051). Treatment with opicapone 5 mg (p=0·056) or 25 mg (p=0·080) was not significantly different from treatment with placebo.

Discovery of a long-acting, peripherally selective inhibitor of catechol- O -methyltransferase

Kiss, László E.,Ferreira, Humberto S.,Torr?o, Leonel,Bonifácio, Maria Jo?o,Palma, P. Nuno,Soares-Da-Silva, Patrício,Learmonth, David A.

supporting information; experimental part, p. 3396 - 3411 (2010/09/05)

Novel nitrocatechol-substituted heterocy...

923287-50-7 Upstream products

  • 1044137-00-9

    3-(5-(3,4-bis(benzyloxy)-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-2,5-dichloro-4,6-dimethylpyridine 1-oxide

  • 123-54-6


  • 769-28-8


  • 23819-92-3


Relevant Products